Mark Stesin, MD
Endocrinology, Diabetes & Metabolism · Robbinsdale, MNNPI 1750430823
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.7% of the total across 95 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Medtronic accounts for 66.6% of it on its own, with 13 other manufacturers making up the rest. Reporting peaked in 2019 at $941 and has fallen 83.1% since, to $159 in 2025.
Across 95 payments — averaging $36.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$2K
- Mannkind Corporation$396
- Amphastar Pharmaceuticals, Inc.$319
- Lilly USA, LLC$107
- Bayer$63
- Boehringer Ingelheim$59
- plus $200 from 8 others
What the payments were for
- Travel & lodging$201%
- Food & beverage$3,34998%
- Gifts$592%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 48 | $2,284 |
| Mannkind Corporation | 13 | $396 |
| Amphastar Pharmaceuticals, Inc. | 8 | $319 |
| Lilly USA, LLC | 6 | $107 |
| Bayer | 4 | $63 |
| Boehringer Ingelheim | 4 | $59 |
| AbbVie | 2 | $48 |
| Recordati_rare_diseases_inc. | 2 | $35 |
| Novo Nordisk | 2 | $28 |
| AstraZeneca | 2 | $23 |
| Amgen | 1 | $22 |
| Dexcom, Inc. | 1 | $22 |
| Lifescan, Inc. | 1 | $13 |
| Sanofi-aventis U.S. LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Minimed 670G System$461
- MINIMED 780G$459
- INPEN SMART INSULIN DELIVERY SYSTEM$207
- AFREZZA$117
- Enlite Sensor$108
- BAQSIMI$106
- MINIMED 770G$101
How this compares
$3,428 in reported general payments places this provider in the 70th percentile of 120 endocrinology, diabetes & metabolism providers in Minnesota.
See all endocrinology, diabetes & metabolism providers in Minnesota →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 271 | $353,212 |
| OzempicSemaglutide | 178 | $260,389 |
| MounjaroTirzepatide | 81 | $116,666 |
| JanuviaSitagliptin Phosphate | 75 | $75,030 |
| SynthroidLevothyroxine Sodium | 456 | $52,523 |
| FarxigaDapagliflozin Propanediol | 30 | $48,342 |
| RybelsusSemaglutide | 30 | $45,807 |
| TradjentaLinagliptin | 39 | $40,777 |
| TrulicityDulaglutide | 26 | $37,118 |
| KerendiaFinerenone | 20 | $33,042 |
| ProliaDenosumab | 17 | $29,246 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 41 | $28,921 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 33 | $26,125 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 93 | $24,308 |
| HumalogInsulin Lispro | 69 | $20,301 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta | $59 | $393,989310 claims |
| Novo NordiskOzempic, Rybelsus, Novolog | $28 | $320,346235 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro | $107 | $176,067195 claims |
| AbbVieSynthroid | $48 | $52,523456 claims |
| AstraZenecaFarxiga | $23 | $48,34230 claims |
| BayerKerendia | $63 | $33,04220 claims |
| AmgenProlia | $22 | $29,24617 claims |
| Sanofi-aventis U.S. LLCLantus | $11 | $2,26115 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 120 endocrinology, diabetes & metabolism providers in Minnesota.
Other endocrinology, diabetes & metabolism in Robbinsdale
- Richard BergenstalSt Louis Park$595K
- Farha KhanCoon Rapids$349K
- Mark HolmSaint Cloud$318K
- Marjorie Ann MalbasRochester$222K
- Anders CarlsonSt Louis Park$163K
- Maria CaramoriMinneapolis$147K
- Irina BancosRochester$114K
- Sidney JonesChaska$67K
- Maria CastroRochester$63K
- Marius StanRochester$59K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.